



**Healthcare Special Opportunities Fund**

Interim Financial Statements

June 30, 2018

# Healthcare Special Opportunities Fund

## Statements of Financial Position (unaudited)

As at June 30, 2018 and December 31, 2017

	2018	2017
<b>Assets</b>		
<b>Current assets</b>		
Financial assets at fair value through profit or loss (note 3)	\$ 43,403,046	\$ 40,660,436
Cash	7,865,229	3,370,123
Accrued dividends	67,179	79,648
Accrued interest	25,019	460
Receivable for investments sold	-	192,559
<b>Total assets</b>	<b>51,360,473</b>	<b>44,303,226</b>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Performance fees	1,170,411	718,902
Accrued expenses	92,447	114,209
Distributions payable to unitholders	230,829	-
Management fees payable	36,869	33,884
<b>Total liabilities (excluding Net Assets attributable to holders of redeemable units)</b>	<b>1,530,556</b>	<b>866,995</b>
<b>Net Assets attributable to holders of redeemable units (note 4)</b>	<b>\$ 49,829,917</b>	<b>\$ 43,436,231</b>
<b>Net Assets attributable to holders of redeemable units per class</b>		
Class A	\$ 48,862,014	\$ 42,578,398
Class U	\$ 967,903	\$ 857,833
<b>Net Assets attributable to holders of redeemable units per class per unit (note 4)</b>		
Class A	\$ 12.27	\$ 10.69
Class U	\$ 15.89	\$ 13.86

Approved on behalf of LDIC Inc., as manager of the Healthcare Special Opportunities Fund.

/s/ Michael B. Decter

Michael B. Decter, Director

/s/ Beryl McCallum

Beryl McCallum, Director

# Healthcare Special Opportunities Fund

## Statements of Comprehensive Income (unaudited)

For the six-month period ended June 30,

	2018	2017
<b>Net gain (loss) on financial instruments</b>		
Dividend income	\$ 234,301	\$ 684,561
Interest for distribution purposes	38,422	4,561
Foreign exchange gain (loss)	(107,814)	60,731
Other changes in fair value on financial assets and financial liabilities at fair value through profit or loss		
Net realized gain (loss) on sale of investments	3,805,583	4,720,804
Change in unrealized appreciation (depreciation) in value of investments	3,715,700	1,321,505
Change in unrealized appreciation (depreciation) in value of foreign exchange from currency	89,855	(543,611)
<b>Net gain (loss) on financial instruments</b>	<b>7,776,047</b>	<b>6,248,551</b>
<b>Expenses (note 5)</b>		
Performance fees	451,509	-
Management fees	320,032	500,582
Custodian fees	4,092	4,184
Audit fees	10,326	12,972
Legal fees	5,515	5,579
Valuation fees	15,310	16,765
Independent review committee fees	1,494	1,675
Transaction costs (note 7)	53,116	116,466
Filing fees	7,931	12,832
Securityholder reporting costs	20,964	18,084
Other expenses	16,247	34,740
<b>Total operating expenses</b>	<b>906,536</b>	<b>723,879</b>
<b>Operating profit (loss)</b>	<b>6,869,511</b>	<b>5,524,672</b>
Withholding taxes (note 6)	(23,283)	(72,019)
<b>Increase (decrease) in Net Assets attributable to holders of redeemable units from operations (excluding distributions)</b>	<b>\$ 6,846,228</b>	<b>\$ 5,452,653</b>
<b>Increase (decrease) in Net Assets attributable to holders of redeemable units per class from operations (excluding distributions)</b>		
Class A	\$ 6,713,016	\$ 4,577,443
Class U	\$ 133,212	\$ 875,210
<b>Average number of units outstanding for the period per class</b>		
Class A	3,983,192	6,222,342
Class U	61,043	912,875
<b>Increase (decrease) in Net Assets attributable to holders of redeemable units per unit from operations (excluding distributions)</b>		
Class A	\$ 1.69	\$ 0.74
Class U	\$ 2.18	\$ 0.96

The accompanying notes are an integral part of these financial statements

## Healthcare Special Opportunities Fund

### Statements of Changes in Net Assets Attributable to Holders of Redeemable Units (unaudited)

For the six-month period ended June 30,

	2018	2017	2018	2017
	Class A		Class U	
<b>Net Assets attributable to holders of redeemable units at beginning of period</b>	\$ 42,578,398	\$ 56,975,850	\$ 857,833	\$ 10,910,684
<b>Increase (decrease) in Net Assets attributable to holders of redeemable units from operations (excluding distributions)</b>	<b>6,713,016</b>	4,577,443	<b>133,212</b>	875,210
<b>Redeemable unit transactions</b>				
Class U redeemable units converted into Class A redeemable units	14,250	167,053	(14,250)	(167,053)
Normal course issuer bid Class A units repurchased and cancelled	(4,286)	-	-	-
	<b>9,964</b>	167,053	<b>(14,250)</b>	(167,053)
<b>Distributions to holders of redeemable units</b>				
From net investment income	(439,364)	-	(8,892)	-
	<b>(439,364)</b>	-	<b>(8,892)</b>	-
<b>Net increase (decrease) in Net Assets attributable to holders of redeemable units</b>	<b>6,283,616</b>	4,744,496	<b>110,070</b>	708,157
<b>Net Assets attributable to holders of redeemable units at end of period</b>	\$ <b>48,862,014</b>	\$ 61,720,346	\$ <b>967,903</b>	\$ 11,618,841
			<b>2018</b>	2017
			<b>Total</b>	
<b>Net Assets attributable to holders of redeemable units at beginning of period</b>			\$ 43,436,231	\$ 67,886,534
<b>Increase (decrease) in Net Assets attributable to holders of redeemable units from operations (excluding distributions)</b>			<b>6,846,228</b>	5,452,653
<b>Redeemable unit transactions</b>				
Redemption of redeemable units			-	-
Normal course issuer bid Class A units repurchased and cancelled			(4,286)	-
			<b>(4,286)</b>	-
<b>Distributions to holders of redeemable units</b>				
Return of capital			(448,256)	-
			<b>(448,256)</b>	-
<b>Net increase (decrease) in Net Assets attributable to holders of redeemable units</b>			<b>6,393,686</b>	5,452,653
<b>Net Assets attributable to holders of redeemable units at end of period</b>			\$ <b>49,829,917</b>	\$ 73,339,187

The accompanying notes are an integral part of these financial statements

# Healthcare Special Opportunities Fund

## Statements of Cash Flows (unaudited)

For the six-month period ended June 30,

	2018	2017
<b>Cash flows from (used in) operating activities</b>		
Increase (decrease) in Net Assets attributable to holders of redeemable units from operations (excluding distributions)	\$ 6,846,228	\$ 5,452,653
Adjustments for:		
Foreign exchange (gain) loss	107,814	(60,731)
Net realized (gain) loss on sale of investments	(3,805,583)	(4,720,804)
Change in unrealized (appreciation) depreciation in value of investments	(3,715,700)	(1,321,505)
Purchases of investments	(17,999,172)	(31,604,292)
Proceeds from sale of investments	22,970,404	39,465,772
Accrued dividends	12,469	8,290
Accrued interest	(24,559)	246
Accrued expenses	(21,762)	8,053
Performance fees	451,509	-
Management fees payable	2,985	2,436
<b>Net cash from (used in) operating activities</b>	<b>4,824,633</b>	<b>7,230,118</b>
<b>Cash flows from (used in) financing activities</b>		
Distributions paid to holders of redeemable units, net of reinvested distributions	(217,427)	-
Normal course issuer bid Class A units repurchased and cancelled	(4,286)	-
<b>Net cash from (used in) financing activities</b>	<b>(221,713)</b>	<b>-</b>
Foreign exchange gain (loss)	(107,814)	60,731
Net increase (decrease) in cash	4,602,920	7,230,118
Cash at beginning of period	3,370,123	7,532,931
<b>Cash at end of period</b>	<b>\$ 7,865,229</b>	<b>\$ 14,823,780</b>
<b>Supplemental Cash Flow Information:</b>		
Dividends received, net of withholding taxes	\$ 223,487	\$ 620,832
Interest received	13,863	4,807

# Healthcare Special Opportunities Fund

## Schedule of Investment Portfolio

As at June 30, 2018 (unaudited)

Par Value/ Number of Shares	Description	Maturity Date /Expiry Date	Coupon Rate	Average Cost (\$)	Fair Value (\$)	% of Net Assets
<b>Bonds - Canada</b>						
<b>Corporate Bonds</b>						
150,000	2576560 Ontario Inc.	December 13, 2019	8.000%	150,000	150,000	
1,000,000	Organigram Holdings	January 31, 2020	6.000%	1,000,000	1,060,000	
	<b>Total Bonds</b>			<u>1,150,000</u>	<u>1,210,000</u>	<u>2.4</u>
<b>Equities - Canada</b>						
<b>Consumer Discretionary</b>						
36,300	Park Lawn Corp.			<u>676,041</u>	<u>883,179</u>	<u>1.8</u>
<b>Consumer Staples</b>						
186,100	GreenSpace Brands Inc.			199,833	193,545	
250,000	GreenSpace Brands Inc., Warrants	February 22, 2019		54,990	22,500	
744,600	Sweet Natural Trading Co.			89,352	44,676	
62,500	Village Farms International Inc.			<u>356,026</u>	<u>385,000</u>	
				<u>700,201</u>	<u>645,721</u>	<u>1.3</u>
<b>Health Care</b>						
37,500	2576560 Ontario Inc., Warrants	December 13, 2020		-	-	
1,170,215	Akumin Inc.			3,237,727	6,472,973	
222,500	CannTrust Holdings Inc., Warrants	May 9, 2018		-	24,475	
40,000	CannTrust Holdings Inc.			354,512	313,200	
208,000	Canopy Health Innovations			398,000	3,028,480	
481,313	Grey Wolf Animal Health Inc.			425,000	424,999	
70,000	Hydrophocary Corp.			352,709	371,000	
332,500	Luminor Medical Technologies Inc., Warrants	September 27, 2019		-	38,238	
700,000	Microbix Biosystems Inc.			210,000	206,500	
350,000	Microbix Biosystems Inc., Warrants	October 18, 2020		-	-	
165,500	Profound Medical Corp.			162,372	158,880	
665,000	RISE Life Science Corp.			99,750	242,725	
145,000	TRC Management Holdings Corp.			<u>507,500</u>	<u>507,500</u>	
				<u>5,747,570</u>	<u>11,788,970</u>	<u>23.6</u>
<b>Industrials</b>						
55,100	Morneau Shepell Inc.			<u>1,169,545</u>	<u>1,497,618</u>	<u>3.0</u>
<b>Information Technology</b>						
445,000	Reliq Health Technologies Inc.			498,400	827,700	
35,700	TECSYS Inc.			<u>345,981</u>	<u>549,780</u>	
				<u>844,381</u>	<u>1,377,480</u>	<u>2.8</u>
<b>Materials</b>						
1,000,000	Good Natured Products Inc., Warrants	December 21, 2018		-	1	-
<b>Equities - United States</b>						
<b>Health Care</b>						
5,800	Aetna Inc.			1,202,024	1,400,026	
11,400	Becton Dickinson and Co.			2,556,871	3,592,455	
5,300	Centene Corp.			623,273	859,002	
10,700	Johnson & Johnson			1,511,680	1,707,890	
19,643	Medtronic PLC			1,980,376	2,212,098	
14,700	Merck & Co Inc			1,023,301	1,173,757	
398,000	R1 RCM Inc			1,814,534	4,544,383	
8,710	Stryker Corp			<u>1,185,696</u>	<u>1,934,715</u>	

# Healthcare Special Opportunities Fund

## Schedule of Investment Portfolio

As at June 30, 2018 (unaudited)

Number of Shares	Description	Average Cost (\$)	Fair Value (\$)	% of Net Assets
<b>Equities - United States (continued)</b>				
<b>Health Care</b>				
5,800	Thermo Fisher Scientific Inc.	1,603,305	1,580,389	
14,700	UnitedHealth Group Inc.	3,015,761	4,744,144	
80,200	Zymeworks Inc.	1,487,810	1,559,269	
		<u>18,004,631</u>	<u>25,308,128</u>	<u>50.8</u>
<b>Real Estate</b>				
33,000	Physicians Realty Trust	633,221	691,949	1.4
	<b>Total Equities</b>	<u>27,775,590</u>	<u>42,193,046</u>	<u>84.7</u>
	<b>Transaction costs</b>	(25,602)		
	<b>Total Investments</b>	<u>28,899,988</u>	<u>43,403,046</u>	<u>87.1</u>
	<b>Other Assets, Less Liabilities</b>		<u>6,426,871</u>	<u>12.9</u>
	<b>Net Assets Attributable to Holders of Redeemable Units</b>		<u>\$ 49,829,917</u>	<u>100.0</u>

# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

---

### 1. GENERAL INFORMATION

The Healthcare Special Opportunities Fund (the “Fund”) is a closed-end investment trust established under the laws of the Province of Ontario on June 26, 2015. LDIC Inc. (the “Manager”) is the Trustee and Manager of the Fund. The Fund was listed on the Toronto Stock Exchange (“TSX”) and commenced operations on July 15, 2015 when it first issued units through an initial public offering. The address of the Fund’s registered office is LDIC Inc., 130 King Street West, Suite 2130, Toronto, Ontario. These financial statements were authorized for issue by the Manager on August 17, 2018.

The investment objective of the Fund is principally set up to provide holders of units with long-term total return through distributions and capital appreciation of the Fund’s investment portfolio by investing in equity and debt securities of issuers that derive a significant portion of their revenue or earnings from medical and healthcare products and/or services.

### 2. BASIS OF PRESENTATION

These interim financial statements of the Fund have been prepared in compliance with International Financial Reporting Standards (“IFRS”), including International Accounting Standards (“IAS”) 34: Interim Financial Reporting, as published by the International Accounting Standards Board (“IASB”).

The policies applied in these financial statements are based on IFRS standards issued and outstanding as of August 17, 2018, which is the date on which the interim statements were authorized for issue by the Manager.

In the preparation of these interim financial statements, management has made judgments, estimates and assumptions that affect the application of the Fund’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

These financial statements have been presented in Canadian dollars, which is the Fund’s functional currency.

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### (a) New accounting standards and interpretations

Effective January 1, 2018 the Fund adopted IFRS 9, Financial Instruments - Classification and Measurement (“IFRS 9”). The new standard requires financial assets to be classified as amortized cost, fair value through profit or loss (“FVTPL”), or fair value through other comprehensive income (“FVOCI”) based on the entity’s business model for managing the financial assets and the contractual cash flow characteristics of these assets. Assessment and decision on the business model approach used is an accounting judgement.

The classification and measurement of financial liabilities remain generally unchanged with the exception of liabilities recorded at FVTPL. For these liabilities, fair value changes attributable to changes in the entity’s own credit risk are to be presented in other comprehensive income unless they affect amounts recorded in income.

Upon transition to IFRS 9, the Fund’s financial assets and financial liabilities previously classified as FVTPL under IAS 39, Financial Instruments – Recognition and Measurement (“IAS 39”) continue to be classified in the same category and there were no changes in the measurement attributes. The adoption of IFRS 9 has also been applied retrospectively and did not result in any changes in the prior period.

#### (b) Foreign currency translation

The Fund’s functional and presentation currency is the Canadian dollar. Foreign currency purchases and sales of investments and foreign currency dividend and interest income and expenses are translated into Canadian dollars at the rate of exchange prevailing at the date of the transactions.



# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

---

Foreign exchange gains (losses) on purchases and sales of foreign currencies are included in the Statements of Comprehensive Income – Foreign exchange gain (loss).

The fair values of investments and other assets and liabilities denominated in foreign currencies are translated into Canadian dollars at the rate of exchange prevailing at the Statement of Financial Position date.

### (c) Financial instruments

The Fund classifies and measures financial instruments in accordance with IFRS 9. The Fund's investments and derivative assets and liabilities are measured at fair value through profit or loss ("FVTPL"). All other financial assets and liabilities are measured at amortized cost. Under this method, financial assets and liabilities reflect the amounts required to be received or paid, discounted when appropriate, at the financial instrument's effective interest rate. The fair values of the Fund's financial assets and liabilities that are not carried at FVTPL approximate their carrying amounts due to their short-term nature.

### (d) Fair value measurements

Financial instruments are valued at their fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets is based on quoted market prices at the close of trading on the reporting date. The Fund uses the last traded market price for both financial assets and financial liabilities where the last traded price falls within that day's bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Manager determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances.

The Fund uses a three-tier hierarchy as a framework for disclosing fair value based on inputs used to value the Fund's investments. The hierarchy of inputs is summarized below:

- Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 - inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Changes in valuation methods may result in transfers into or out of an investment's assigned level.

A valuation hierarchy table has been included in Note 10, Fair Value Disclosure.

### (e) Impairment of financial assets

IFRS 9 requires that an entity recognize a loss allowance for expected credit losses on financial assets which are measured at amortized costs or FVOCI. Financial assets held by the Fund which are measured at FVTPL will not be subject to the new impairment requirements.

With respect to loans and receivables, the Funds consider both historical analysis and forward looking information in determining any expected credit loss. As at the period end date, all loans and receivables are due to be settled within the short term. The Funds consider the probability of default to be close to zero as these instruments have a low risk of default and the counterparties have a strong capacity to meet their contractual obligation in the near term. Given the limited exposure of the Funds to credit risk, no loss allowance has been recognized as any such impairment will not have a significant impact on the financial statements.

### (f) Cash

Cash comprises of deposits held at financial institutions.

# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

---

**(g) Multi-class allocation**

Expenses, realized and unrealized gains/losses and income generally are allocated among the classes on a pro-rata basis.

Class-specific management fees are not allocated and do not require allocation.

**(h) Transaction costs**

Transaction costs, such as brokerage commissions incurred in the purchase and sale of securities, are expensed and are included in "Transaction costs" in the Statements of Comprehensive Income.

**(i) Investment transactions**

Investment transactions are accounted for on the trade date. All income, net realized gains (losses), unrealized appreciation (depreciation) in the value of investments and transaction costs are attributable to investments that are deemed held for trading.

**(j) Revenue recognition**

- The interest for distribution purposes shown on the Statements of Comprehensive Income represents the coupon interest received by the Fund accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed-income securities, except for zero coupon bonds, which are amortized on a straight-line basis.
- Dividend income is recorded on the ex-dividend date and is gross of withholding taxes.
- Realized gains and losses on investments and unrealized appreciation (depreciation) in the value of investments are calculated with reference to the average cost of the related investments.

**(k) Increase (decrease) in Net Assets attributable to holders of redeemable units per unit**

The increase (decrease) in Net Assets attributable to holders of redeemable units per unit in the Statements of Comprehensive Income represents the net increase (decrease) in Net Assets attributable to holders of redeemable units per unit, divided by the weighted average number of units outstanding during the period of that class of units.

**(l) Accounting standards issued but not yet adopted**

The Fund has determined there are no material implications to the Fund's financial statements arising from IFRS issues but not yet effective.

**(m) Critical accounting estimates and judgments**

- Fair value measurements of financial instruments not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets. Fair values of such instruments are determined using valuation techniques and may be determined using reputable pricing sources (such as pricing agencies) or indicative prices from market makers. Broker quotes as obtained from the pricing sources may be indicative and not executable or binding. When no market data is available, the Fund may value positions using its own models, which are usually based on valuation methods and techniques generally, recognized as standard within the industry.

# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

---

- Classification and measurement of financial instruments and application of fair value option

In classifying and measuring financial instruments held by the Fund, the Manager is required to make significant judgments in determining the most appropriate classification in accordance with IFRS 9. The Manager has assessed the Fund's business models, the manner in which all financial assets and financial liabilities are managed and performance evaluates as a group on a fair value basis, and concluded that FVTPL in accordance with IFRS 9 provides the most appropriate classification of the Fund's financial instruments.

#### 4. UNITS OF THE FUND

The Fund is authorized to issue an unlimited number of units of each class. The Class A units are denominated in Canadian dollars, and the Class U units are denominated in U.S. dollars. The Class U units will not be listed on a stock exchange, but are convertible into Class A units on a weekly basis for liquidity. It is expected that liquidity for the Class U units will be obtained primarily by means of conversion into Class A units and the sale of such Class A units on a stock exchange.

Units may be redeemed at the option of unitholders by tendering units of the Fund by the second last business day of July for redemptions ("Annual Redemption Date") commencing in 2017. Units must be properly surrendered for redemption at least 30 days prior to an Annual Redemption Date in each year. Unitholders whose units are redeemed on the Annual Redemption Date will receive a redemption price per unit equal to 100% of the Net Asset Value ("NAV") per unit of the applicable class on an Annual Redemption Date (less any costs associated with the redemption including brokerage costs).

In addition to the annual redemption right, Unitholders may surrender units at any time for redemption on the second last Business Day (a "Business Day" being a day other than a Saturday, Sunday or statutory holiday in Toronto, Ontario or any other day the TSX is not open for trading) in a month (a "Monthly Redemption Date"), subject to certain conditions. Unitholders surrendering a Class A unit for redemption on a Monthly Redemption Date will receive a redemption price equal to the lesser of (a) 95% of the "weighted average trading price" of the Class A units on the principal market on which the Class A units are quoted for trading, the TSX, during the 15 trading days preceding the applicable Monthly Redemption Date; and (b) the "closing market price" of the Class A units on the principal market on which the Class A units are quoted for trading on the applicable Monthly Redemption Date (the "Monthly Redemption Amount" less, in each case, any costs associated with the redemption, including brokerage costs). Unitholders surrendering a Class U unit for redemption on a Monthly Redemption Date will receive in U.S. dollars an amount equal to the U.S. dollar equivalent of the product of (i) the Monthly Redemption Amount and (ii) a fraction, the numerator of which is the most recently calculated NAV per unit of a Class U unit and the denominator of which is the most recently calculated NAV per unit of a Class A unit, less any costs associated with the redemption, including brokerage costs.

On June 22, 2017, the Fund announced a normal course issuer bid ("NCIB") to repurchase its Class A units. The NCIB will not be renewed and expire on July 27, 2018.

# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

### Issued

During the period, unit transactions of the Fund were as follows:

	2017	
	Number of Class A Units	Number of Class U Units
Units outstanding at January 1, 2018	3,982,457	61,900
Normal course issuer bid Class A units repurchased and cancelled	(400)	-
Class U redeemable units converted to Class A redeemable units	1,296	(1,000)
Units outstanding at June 30, 2018	3,983,353	60,900
	2017	
	Number of Class A Units	Number of Class U Units
Units, outstanding at January 1, 2017	6,217,302	916,757
Issuance of redeemable units	-	-
Class U redeemable units converted to Class A redeemable units	16,880	(13,000)
Units, outstanding at June 30, 2017	6,234,182	903,757

On June 30, 2018, the Fund's closing market price was \$11.80 per Class A unit (December 31, 2017 - \$10.26 per Class A unit).

### 5. RELATED PARTY TRANSACTIONS

As at June 30, 2018, the Manager of the Fund and certain Directors and Officers of the Manager held a total of 294,328 (2017 - 294,328) Class A units of the Fund.

#### Management fees, performance fees and operating expenses

The Manager provides investment and administrative services to the Fund. In consideration for these services, the Manager receives a 1.25% fee per annum based on a percentage of the Net Assets of the Fund calculated daily and payable monthly.

The Manager is entitled to be paid a performance fee (the "Performance Fee") from the Fund in respect of investments in the private equity investments (the "Private Portfolio") including, for the purpose of calculating the Performance Fee, securities of private issuers in the Private Portfolio that have become publicly traded and public securities received on the disposition of securities of a private issuer in the Private Portfolio. The amount of the Performance Fee shall be determined as of the date of disposition (the "Determination Date") for cash proceeds of each such investment.

The Performance Fee in respect of each investment will be equal to 20% of the amount by which the cash proceeds of disposition exceed 106% of the Threshold Amount (as defined below) calculated on a cumulative annual basis plus applicable taxes.

The Performance Fee shall be calculated and accrue daily and be paid upon each Determination Date; however, no Performance Fee shall be paid in respect of any dispositions of securities of private issuers in the Private Portfolio unless on the Determination Date the proceeds of disposition of the investment exceed 107% of the original book value of the investment (the "Threshold Amount").

The Fund is responsible for the payment of all expenses relating to its operations and the carrying on of its business. These expenses include, but are not limited to, administration and accounting costs, the costs of any back-office service provider retained by the Manager, transaction costs, audit and legal fees, custodian fees, the costs of preparing and distributing annual and semi-annual financial statements, unitholder reports and investor communications. At certain times, the Manager may pay a portion of the expenses otherwise payable by the Fund.

# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

---

### 6. TAXATION OF THE FUND AND ALLOCATION TO UNITHOLDERS

The Fund qualifies as a mutual fund trust as defined in the *Income Tax Act* (Canada) (the “Act”). Pursuant to the terms of the Declaration of Trust, the Fund pays or makes payable in the calendar year to the unitholders all the net income and such portion of the net capital gains that will result in the Fund paying no tax under the current provisions of the Act. As a result, under existing tax legislation, the net income and net capital gains are taxable in the hands of the unitholders of the Fund. Accordingly, no provision for Canadian income taxes has been made in these financial statements.

The Fund currently incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income and gains are recorded on a gross basis and the related withholding taxes are shown separately in the Statements of Comprehensive Income.

The Fund has accumulated capital loss carryforwards as of December 31, 2017 of \$7,119,695 (2016 - \$7,119,695), which may be applied against future years’ capital gains and can be carried forward indefinitely. As of December 31, 2017, there was a \$525,015 (2016 - \$525,015) in non-capital losses available in the Fund, which can be carried forward until 2036.

### 7. TRANSACTION COSTS

Commissions and other transaction fees paid for portfolio transactions for the period ended June 30, 2018 were \$53,116 (2017 - \$116,466).

### 8. SOFT DOLLAR COMMISSIONS

In addition to covering brokerage services on security transactions, commissions paid to certain brokers may also cover research services provided to the Manager. The value of the research services included in the commissions paid by the Fund to those brokers for the periods ended June 30, 2018 and 2017 was \$12,873 and \$31,305, respectively.

### 9. FINANCIAL RISK MANAGEMENT

In the normal course of operations, the Fund’s activities expose it to a variety of financial risks: credit risk, liquidity risk and market risk (which includes interest rate risk, currency risk, other price risk and concentration risk). The value of investments in a Fund’s portfolio can fluctuate on a daily basis as a result of changes in interest rates, economic conditions and market news related to specific securities in the portfolio. The level of risk depends on the Fund’s objectives and the type of securities that it holds. In order to mitigate risk, depending on conditions, the Manager diversifies the portfolio based on criteria such as asset class, country, industry and currency. Significant risks that are relevant to the Fund are discussed below. “Net Assets” below is defined as Net Assets attributable to unitholders.

#### (a) Credit risk

Credit risk represents the potential loss that the Fund would incur if counterparties failed to perform in accordance with the terms of their obligations to the Fund. The Manager only trades with approved counterparties and monitors reporting that includes approved counterparty listings, trade volumes and exposure reports. The risk of default is considered minimal, as delivery of securities sold is only made once the Fund has received payment. Payment is made on a purchase once the securities have been received by the Fund. The trade will fail if either party fails to meet its obligation. The Fund maintains all of its cash and cash equivalents at the custodian or in overnight deposits with approved counterparties and ensures that appropriate collateral is received.

As at June 30, 2018 and December 31, 2017, the Fund had directly invested in debt instruments with the following Standard & Poor’s credit ratings:

# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

Portfolio by rating category	As a % of Net Assets	
	June 30, 2018	December 31, 2017
NR	2.4%	0.3%

### (b) Liquidity risk

Liquidity risk is the risk that the Fund will encounter difficulty in meeting its obligations associated with its financial liabilities. The Fund's primary exposure to liquidity risk relates to its unitholders' rights to redeem their units on any valuation date. Liquidity risk is managed by retaining sufficient cash and cash equivalent positions and investing the majority of the Fund's assets in portfolio investments that are traded in an active market and can be readily disposed of. There can be no assurance that an active trading market for the investments will exist at all times, or that the prices at which the securities trade accurately reflect their values.

Thin trading in a security could make it difficult to liquidate holdings quickly. The Manager considers market depth and the relationship between liquidity and size of the position as part of the criteria for approval of a new investment and in its periodic re-evaluation of the investment.

### (c) Market risk

Market risk is the risk that fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The Fund's activities may expose it to different types of market risk including currency risk, interest rate risk, other price risk and concentration risk.

#### (i) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Interest rate risk arises on interest-bearing financial instruments.

As at June 30, 2018 and December 31, 2017, the Fund's direct exposure to debt instruments by maturity was as follows:

		Less than 1 year (\$)	1 - 5 years (\$)	More than 5 years (\$)	Total (\$)
Interest rate exposure	June 30, 2018	-	1,210,000	-	1,210,000
	December 31, 2017	-	150,000	-	150,000

As at June 30, 2018, should interest rates have decreased or increased by 0.25% with all other variables remaining constant, the increase or decrease in Net Assets for the year would amount to approximately \$4,518 (December 31, 2017 - \$685). In practice, the actual trading results may differ, and the difference could be material.

#### (ii) Currency risk

Currency risk is the risk that the fair value of financial instruments denominated in currencies other than the Canadian dollar, which is the Fund's reporting currency, will fluctuate because of changes in foreign exchange rates.

	June 30, 2018		December 31, 2017	
	Currency Exposure (\$)	Percentage of Net Assets (%)	Currency Exposure (\$)	Percentage of Net Assets (%)
U.S. dollar	40,350,732	81.0	35,308,961	81.3

# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

As at June 30, 2018, if the Canadian dollar had strengthened or weakened by 5% in relation to all foreign currencies represented in the portfolio, with all other variables remaining constant, Net Assets would have decreased or increased by approximately \$2,017,537 (December 31, 2017 - \$1,765,448). In practice, the actual results may differ and the difference could be material.

### (iii) Other price risk

Other price risk represents the risk that the value of financial instruments will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment.

The Fund is exposed to other price risk from investments in equities. As at June 30, 2018, approximately 84.67% (December 31, 2017 – 93.3%) of the Fund's Net Assets were held directly in equities. If equity prices on the exchanges increased or decreased by 5% as at June 30, 2018, the Net Assets of the Fund would have increased or decreased by approximately \$2,109,652, or 4.2% (December 31, 2017 - \$2,025,522, or 4.7%) with all other factors remaining constant. In practice, the actual results may differ and the difference could be material.

### (iv) Concentration risk

Concentration risk arises as a result of the concentration of exposures within the same category, whether it is geographical location, product type, industry sector or counterparty type. The following is a summary of the Fund's concentration risk:

<b>Investment Sector</b>	<b>June 30, 2018</b>	<b>December 31, 2017</b>
Corporate Bonds	2.4%	0.3%
Consumer Discretionary	1.8%	1.9%
Consumer Staples	1.3%	1.2%
Health Care	74.4%	82.0%
Industrials	3.0%	3.7%
Information Technology	2.8%	1.8%
Real Estate	1.4%	2.7%
Net Other Assets/Liabilities	12.9%	6.4%
<b>Total</b>	<b>100.0%</b>	<b>100.0%</b>

## 10. FAIR VALUE DISCLOSURE

The following tables illustrate the classification of the Fund's assets and liabilities measured at fair value within the fair value hierarchy as at June 30, 2018 and December 31, 2017:

	<b>Financial Assets at Fair Value as at June 30, 2018</b>			
	<b>Level 1 (\$)</b>	<b>Level 2 (\$)</b>	<b>Level 3 (\$)</b>	<b>Total (\$)</b>
<b>Equities</b>	38,102,178	44,676	3,960,979	42,107,833
<b>Warrants</b>	22,500	62,713	-	85,213
<b>Bonds</b>	-	-	1,210,000	1,210,000
	<b>38,124,678</b>	<b>107,389</b>	<b>5,170,979</b>	<b>43,403,046</b>

**Healthcare Special Opportunities Fund**  
**Notes to Financial Statements (unaudited)**  
**June 30, 2018**

Financial Assets at Fair Value as at December 31, 2017				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)
Equities	38,245,535	472,850	1,660,500	40,378,885
Warrants	85,000	46,551	-	131,551
Bonds	-	-	150,000	150,000
	<b>38,330,535</b>	<b>519,401</b>	<b>1,810,500</b>	<b>40,660,436</b>

The following is a reconciliation of investments in which significant unobservable inputs (Level 3) were used to determine their fair value:

		Bonds	Equities
Balance as at December 31, 2017	\$	<b>150,000</b>	\$ <b>1,660,500</b>
Purchases		<b>1,000,000</b>	-
Sales		-	-
Net transfers in (out)		-	-
Realized gains (losses)		-	-
Change in unrealized appreciation (depreciation) on investments		<b>60,000</b>	<b>2,300,479</b>
Balance as at June 30, 2018	\$	<b>1,210,000</b>	\$ <b>3,960,979</b>
Net change in unrealized appreciation from investments as at June 30, 2018	\$	<b>60,000</b>	\$ <b>2,300,479</b>

		Bonds	Equities
Balance as at December 31, 2016	\$	100,000	\$ 1,052,135
Purchases		150,000	3,136,522
Sales		(100,000)	-
Net transfers in (out)		-	(2,812,727)
Realized gains (losses)		-	-
Change in unrealized appreciation (depreciation) on investments		-	284,570
Balance as at December 31, 2017	\$	150,000	\$ 1,660,500
Net change in unrealized appreciation from investments as at December 31, 2017	\$	-	\$ 330,000

The Fund Manager of the Fund is responsible for performing the valuation of the fair value measurements included in the financial statements, including the level 3 fair values. As at June 30, 2018 and December 31, 2017, the fair values of level 3 securities held by the Fund were comprised of the following securities and the unobservable inputs used in the fair value measurement of these investments were:



# Healthcare Special Opportunities Fund

## Notes to Financial Statements (unaudited)

June 30, 2018

### June 30, 2018

Investment Name	Fair Value (\$)	Valuation Technique	Unobservable inputs
2576560 Ontario Inc.	150,000	Recent Transactions	N/A
Organigram Holdings	1,060,000	Recent Transactions	N/A
Canopy Health Innovations	3,028,480	Recent Transactions	N/A
Grey Wolf Animal Health Inc.	424,999	Recent Transactions	N/A
TRC Management Holdings Corp.	507,500	Recent Transactions	N/A
Total	5,170,979		

### December 31, 2017

Investment Name	Fair Value (\$)	Valuation Technique	Unobservable inputs
2576560 Ontario Inc.	150,000	Amortized Cost	N/A
Canopy Health Innovations	728,000	Recent Transactions	N/A
Grey Wolf Animal Health Inc.	425,000	Recent Transactions	N/A
TRC Management Holdings Corp.	507,500	Recent Transactions	N/A
Total	1,810,500		

There is no significant sensitivity impact related to the fair value of level 3 securities.

## 11. CAPITAL MANAGEMENT

The Fund's investment objective is principally set up to provide unitholders with long-term total return by investing in equity and debt securities of issuers that derive a significant portion of their revenue or earnings from medical and healthcare products and/or services.

The Fund's objective when managing capital is to safeguard the Fund's ability to continue as a going concern in order to provide returns for unitholders, maximize unitholder value and maintain financial strength. The capital of the Fund is divided into two classes, Class A and Class U. The units issued and outstanding represent the capital of the Fund, and shareholders are entitled to distributions when declared.

The Fund manages its capital in accordance with the investment objectives and strategies and the risk management practices outlined in Note 9, Financial Risk Management. The Manager actively monitors the cash position and financial performance to ensure sufficient liquidity to meet operating expenses, distributions, and redemptions.